1887

Abstract

Cryptococcosis causes disseminated disease in AIDS patients. In contrast to what occurs in laboratory conditions, a large capsule is produced by during infection. The aim of this study was to compare the activity of different antifungal agents against 34 clinical isolates of var. without or with capsule induction (CLSI, CLSI-C, respectively), following the CLSI M27A3 document. Capsule induction was obtained by addition of NaHCO and incubation with CO. The geometric means of the MICs, in µg ml, for CLSI and CLSI-C cultures, respectively, were 1.9 and 9.8 for fluconazole; 0.04 and 0.08 for itraconazole; 0.04 and 0.05 for voriconazole; 0.16 and 0.38 for amphotericin B; and 1.6 and 5.6 for 5-flucytosine. Thus fluconazole showed the highest MICs after capsule induction. Determination of antifungal activity after capsule induction may be clinically relevant and could be used to evaluate the correlation between results and clinical outcome.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.036152-0
2012-03-01
2019-10-17
Loading full text...

Full text loading...

/deliver/fulltext/jmm/61/3/384.html?itemId=/content/journal/jmm/10.1099/jmm.0.036152-0&mimeType=html&fmt=ahah

References

  1. Bahn Y. S., Cox G. M., Perfect J. R., Heitman J.. ( 2005;). Carbonic anhydrase and CO2 sensing during Cryptococcus neoformans growth, differentiation, and virulence. . Curr Biol 15:, 2013–2020. [CrossRef][PubMed]
    [Google Scholar]
  2. Barreto de Oliveira M. T., Boekhout T., Theelen B., Hagen F., Baroni F. A., Lazera M. S., Lengeler K. B., Heitman J., Rivera I. N., Paula C. R.. ( 2004;). Cryptococcus neoformans shows a remarkable genotypic diversity in Brazil. . J Clin Microbiol 42:, 1356–1359. [CrossRef][PubMed]
    [Google Scholar]
  3. Bose I., Reese A. J., Ory J. J., Janbon G., Doering T. L.. ( 2003;). A yeast under cover: the capsule of Cryptococcus neoformans. . Eukaryot Cell 2:, 655–663. [CrossRef][PubMed]
    [Google Scholar]
  4. Cherniak R., Morris L. C., Belay T., Spitzer E. D., Casadevall A.. ( 1995;). Variation in the structure of glucuronoxylomannan in isolates from patients with recurrent cryptococcal meningitis. . Infect Immun 63:, 1899–1905.[PubMed]
    [Google Scholar]
  5. Chowdhary A., Randhawa H. S., Sundar G., Kathuria S., Prakash A., Khan Z., Sun S., Xu J.. ( 2011;). In vitro antifungal susceptibility profiles and genotypes of 308 clinical and environmental isolates of Cryptococcus neoformans var. grubii and Cryptococcus gattii serotype B from north-western India. . J Med Microbiol 60:, 961–967. [CrossRef][PubMed]
    [Google Scholar]
  6. CLSI ( 2008;). Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts. Approved Standard. Document M27-A3. Wayne, PA:: Clinical Laboratory Standards Institute;.
    [Google Scholar]
  7. D’Souza C. A., Hagen F., Boekhout T., Cox G. M., Heitman J.. ( 2004;). Investigation of the basis of virulence in serotype A strains of Cryptococcus neoformans from apparently immunocompetent individuals. . Curr Genet 46:, 92–102. [CrossRef][PubMed]
    [Google Scholar]
  8. Dannaoui E., Abdul M., Arpin M., Michel-Nguyen A., Piens M. A., Favel A., Lortholary O., Dromer F..French Cryptococcosis Study Group ( 2006;). Results obtained with various antifungal susceptibility testing methods do not predict early clinical outcome in patients with cryptococcosis. . Antimicrob Agents Chemother 50:, 2464–2470. [CrossRef][PubMed]
    [Google Scholar]
  9. Frases S., Pontes B., Nimrichter L., Rodrigues M. L., Viana N. B., Casadevall A.. ( 2009;). The elastic properties of the Cryptococcus neoformans capsule. . Biophys J 97:, 937–945. [CrossRef][PubMed]
    [Google Scholar]
  10. Granger D. L., Perfect J. R., Durack D. T.. ( 1985;). Virulence of Cryptococcus neoformans. Regulation of capsule synthesis by carbon dioxide. . J Clin Invest 76:, 508–516. [CrossRef][PubMed]
    [Google Scholar]
  11. Janbon G., Himmelreich U., Moyrand F., Improvisi L., Dromer F.. ( 2001;). Cas1p is a membrane protein necessary for the O-acetylation of the Cryptococcus neoformans capsular polysaccharide. . Mol Microbiol 42:, 453–467. [CrossRef][PubMed]
    [Google Scholar]
  12. Liu D., Coloe S., Baird R., Pederson J.. ( 2000;). Rapid mini-preparation of fungal DNA for PCR. . J Clin Microbiol 38:, 471.[PubMed]
    [Google Scholar]
  13. Nguyen M. H., Husain S., Clancy C. J., Peacock J. E., Hung C. C., Kontoyiannis D. P., Morris A. J., Heath C. H., Wagener M., Yu V. L.. ( 2010;). Outcomes of central nervous system cryptococcosis vary with host immune function: results from a multi-center, prospective study. . J Infect 61:, 419–426. [CrossRef][PubMed]
    [Google Scholar]
  14. Osuna A., Carragoso A., Lemos A., Mocho M. L., Gaspar O.. ( 2008;). [Cryptococcosis]. . Acta Med Port 21:, 307–313 (in Portuguese).[PubMed]
    [Google Scholar]
  15. Perfect J. R., Dismukes W. E., Dromer F., Goldman D. L., Graybill J. R., Hamill R. J., Harrison T. S., Larsen R. A., Lortholary O.. & other authors ( 2010;). Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. . Clin Infect Dis 50:, 291–322. [CrossRef][PubMed]
    [Google Scholar]
  16. Rivera J., Feldmesser M., Cammer M., Casadevall A.. ( 1998;). Organ-dependent variation of capsule thickness in Cryptococcus neoformans during experimental murine infection. . Infect Immun 66:, 5027–5030.[PubMed]
    [Google Scholar]
  17. Torres H. A., Prieto V. G., Raad I. I., Kontoyiannis D. P.. ( 2005;). Proven pulmonary cryptococcosis due to capsule-deficient Cryptococcus neoformans does not differ clinically from proven pulmonary cryptococcosis due to capsule-intact Cr. neoformans. . Mycoses 48:, 21–24. [CrossRef][PubMed]
    [Google Scholar]
  18. van Duin D., Cleare W., Zaragoza O., Casadevall A., Nosanchuk J. D.. ( 2004;). Effects of voriconazole on Cryptococcus neoformans. . Antimicrob Agents Chemother 48:, 2014–2020. [CrossRef][PubMed]
    [Google Scholar]
  19. Warn P. A., Sharp A., Guinea J., Denning D. W.. ( 2004;). Effect of hypoxic conditions on in vitro susceptibility testing of amphotericin B, itraconazole and micafungin against Aspergillus and Candida. . J Antimicrob Chemother 53:, 743–749. [CrossRef][PubMed]
    [Google Scholar]
  20. Zaragoza O., Fries B. C., Casadevall A.. ( 2003;). Induction of capsule growth in Cryptococcus neoformans by mammalian serum and CO2. . Infect Immun 71:, 6155–6164. [CrossRef][PubMed]
    [Google Scholar]
  21. Zaragoza O., Mihu C., Casadevall A., Nosanchuk J. D.. ( 2005;). Effect of amphotericin B on capsule and cell size in Cryptococcus neoformans during murine infection. . Antimicrob Agents Chemother 49:, 4358–4361. [CrossRef][PubMed]
    [Google Scholar]
  22. Zaragoza O., Rodrigues M. L., De Jesus M., Frases S., Dadachova E., Casadevall A.. ( 2009;). The capsule of the fungal pathogen Cryptococcus neoformans. . Adv Appl Microbiol 68:, 133–216. [CrossRef][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.036152-0
Loading
/content/journal/jmm/10.1099/jmm.0.036152-0
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error